Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practice.

CONCLUSIONS: Atezolizumab is an active treatment option for platinum-pretreated urinary tract carcinoma, including patients with conditions that typically exclude them from clinical trials. (Trial registration no.: NCT02928406).
PMID: 32399958 [PubMed - in process]

Source: Swiss Medical Weekly - May 3, 2020 Category: General Medicine Authors: Cathomas R, Schardt J, Pless M, Llado A, Mach N, Riklin C, Haefeli J, Fear S, Stenner F Tags: Swiss Med Wkly Source Type: research